Amarin Croissance future

Future contrôle des critères 0/6

Le chiffre d'affaires et le bénéfice de Amarin devraient diminuer respectivement de 3.2% et de 7.7% par an. Le BPA devrait diminuer de 9.2% par an. Le rendement des capitaux propres devrait être de -7.7% dans 3 ans.

Informations clés

-7.7%

Taux de croissance des bénéfices

-9.2%

Taux de croissance du BPA

Biotechs croissance des bénéfices	28.3%
Taux de croissance des recettes	-3.2%
Rendement futur des capitaux propres	-7.7%
Couverture par les analystes	Low
Dernière mise à jour	31 Oct 2024

Mises à jour récentes de la croissance future

Recent updates

Little Excitement Around Amarin Corporation plc's (NASDAQ:AMRN) Revenues

Oct 29

Amarin Corporation plc (NASDAQ:AMRN) Shares Could Be 29% Above Their Intrinsic Value Estimate

Aug 01

Amarin Corporation plc's (NASDAQ:AMRN) 28% Dip In Price Shows Sentiment Is Matching Revenues

Jun 06

Amarin Corporation: Small Signs Of Recovery May Not Be Enough

Apr 16

Little Excitement Around Amarin Corporation plc's (NASDAQ:AMRN) Revenues As Shares Take 27% Pounding

Mar 12

Amarin: Sarissa Is Giving Me Hope Again

Jan 15

Improved Revenues Required Before Amarin Corporation plc (NASDAQ:AMRN) Stock's 26% Jump Looks Justified

Jan 03

Calculating The Fair Value Of Amarin Corporation plc (NASDAQ:AMRN)

Nov 19

Investors Don't See Light At End Of Amarin Corporation plc's (NASDAQ:AMRN) Tunnel

Sep 27

We Think Amarin (NASDAQ:AMRN) Can Afford To Drive Business Growth

Jul 18

Is Amarin (NASDAQ:AMRN) In A Good Position To Deliver On Growth Plans?

Nov 11

Amarin gains as activist Sarissa starts process for special meeting to replace some board members

Oct 11

Prévisions de croissance des bénéfices et des revenus

NasdaqGM:AMRN - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	225	-44	N/A	N/A	3
12/31/2025	179	-82	-8	-8	3
12/31/2024	207	-55	44	51	3
9/30/2024	241	-39	-19	-18	N/A
6/30/2024	265	-34	-9	-9	N/A
3/31/2024	277	-53	1	1	N/A
12/31/2023	307	-59	6	7	N/A
9/30/2023	322	-52	8	9	N/A
6/30/2023	346	-38	-17	-16	N/A
3/31/2023	361	-91	-89	-88	N/A
12/31/2022	369	-106	-181	-180	N/A
9/30/2022	423	-92	-210	-210	N/A
6/30/2022	476	-100	-196	-196	N/A
3/31/2022	536	-22	-147	-147	N/A
12/31/2021	583	8	-67	-67	N/A
9/30/2021	606	-2	-77	-77	N/A
6/30/2021	620	4	-61	-61	N/A
3/31/2021	601	1	-45	-45	N/A
12/31/2020	614	-18	-22	-22	N/A
9/30/2020	590	-16	7	8	N/A
6/30/2020	546	-13	17	19	N/A
3/31/2020	511	-19	30	33	N/A
12/31/2019	430	-23	-12	-9	N/A
9/30/2019	364	-63	-35	-33	N/A
6/30/2019	307	-84	-83	-83	N/A
3/31/2019	259	-117	-123	-123	N/A
12/31/2018	229	-116	-95	-95	N/A
9/30/2018	206	-105	-65	-65	N/A
6/30/2018	198	-92	N/A	-43	N/A
3/31/2018	190	-71	N/A	-29	N/A
12/31/2017	181	-68	N/A	-33	N/A
9/30/2017	166	-73	N/A	-50	N/A
6/30/2017	151	-78	N/A	-62	N/A
3/31/2017	139	-78	N/A	-61	N/A
12/31/2016	130	-86	N/A	-72	N/A
9/30/2016	118	-81	N/A	-76	N/A
6/30/2016	107	-97	N/A	-80	N/A
3/31/2016	91	-147	N/A	-96	N/A
12/31/2015	82	-149	N/A	-84	N/A
9/30/2015	72	-147	N/A	-74	N/A
6/30/2015	64	-141	N/A	-72	N/A
3/31/2015	59	-62	N/A	-57	N/A
12/31/2014	54	-56	N/A	-75	N/A
9/30/2014	48	-52	N/A	-92	N/A
6/30/2014	42	-75	N/A	-117	N/A
3/31/2014	35	-130	N/A	-158	N/A
12/31/2013	26	-166	N/A	-190	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: AMRN devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: AMRN devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: AMRN devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Les revenus de AMRN devraient diminuer au cours des 3 prochaines années ( -3.2% par an).

Croissance élevée des revenus: Les revenus de AMRN devraient diminuer au cours des 3 prochaines années ( -3.2% par an).

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: AMRN devrait être non rentable dans 3 ans.

Amarin Croissance future

Future contrôle des critères 0/6

Informations clés

Mises à jour récentes de la croissance future

Consensus EPS estimates fall by 26%

Price target decreased by 42% to US$1.42

Amarin Corporation plc Provides Revenue Guidance for the Fourth Quarter and Full Year 2023

Consensus EPS estimates fall by 16%

Consensus EPS estimates upgraded to US$0.15 loss, revenue downgraded

Consensus EPS estimates fall by 11%

Recent updates

Nasdaq Grants Amarin Corporation an Additional 180 Calendar Days, or Until May 19, 2025, to Regain Compliance with the Minimum Bid Price Requirement under Nasdaq Listing Rule 5450(a)(1)

Little Excitement Around Amarin Corporation plc's (NASDAQ:AMRN) Revenues

Amarin Corporation plc Announces Executive Changes

Amarin Corporation plc to Report Q3, 2024 Results on Oct 30, 2024

Amarin Corporation plc (NASDAQ:AMRN) Shares Could Be 29% Above Their Intrinsic Value Estimate

Amarin Receives National Reimbursement for Vazkepa® (Icosapent Ethyl) in Portugal

Amarin Corporation plc to Report Q2, 2024 Results on Jul 31, 2024

Amarin Corporation plc's (NASDAQ:AMRN) 28% Dip In Price Shows Sentiment Is Matching Revenues

Amarin Corporation plc Announces Executive Changes

Amarin Corporation Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement of its ADSs Pursuant to Nasdaq Listing Rule 5450(a)(1)

Amarin Corporation plc Receives National Reimbursement for Vazkepa (Icosapent Ethyl) in Greece by Greek Ministry of Health

New minor risk - Profitability

Consensus EPS estimates fall by 26%

New minor risk - Shareholder dilution

First quarter 2024 earnings: EPS exceeds analyst expectations

Amarin Corporation plc (NasdaqGM:AMRN) announces an Equity Buyback for $50 million worth of its shares.

Amarin Corporation plc to Report Q1, 2024 Results on May 01, 2024

Amarin Corporation: Small Signs Of Recovery May Not Be Enough

Amarin Corporation plc Announces New Reduce-It® Analyses Show Vascepa®/Vazkepa® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups

Little Excitement Around Amarin Corporation plc's (NASDAQ:AMRN) Revenues As Shares Take 27% Pounding

Amarin Corporation plc, Annual General Meeting, Apr 18, 2024

Price target decreased by 42% to US$1.42

Amarin Corporation plc to Report Q4, 2023 Results on Feb 29, 2024

Amarin Regains Compliance with Nasdaq Listing Rule

Amarin: Sarissa Is Giving Me Hope Again

Amarin Corporation plc Provides Revenue Guidance for the Fourth Quarter and Full Year 2023

Improved Revenues Required Before Amarin Corporation plc (NASDAQ:AMRN) Stock's 26% Jump Looks Justified

Calculating The Fair Value Of Amarin Corporation plc (NASDAQ:AMRN)

Now 21% undervalued after recent price drop

Amarin Corporation Receives Non-Compliance Notice from Nasdaq

Amarin Corporation Receives Non-Compliance Notice from Nasdaq

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Profitability

Amarin Corporation plc Appoints Jonathan Provoost as New Executive Vice President, Chief Legal & Compliance Officer, Effective November 15, 2023

Amarin Corporation plc to Report Q3, 2023 Results on Nov 01, 2023

Investors Don't See Light At End Of Amarin Corporation plc's (NASDAQ:AMRN) Tunnel

President recently bought US$312k worth of stock

Consensus EPS estimates fall by 16%

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Amarin Corporation plc to Report Q2, 2023 Results on Aug 02, 2023

New minor risk - Share price stability

Consensus EPS estimates upgraded to US$0.15 loss, revenue downgraded

We Think Amarin (NASDAQ:AMRN) Can Afford To Drive Business Growth

Amarin Corporation plc, Annual General Meeting, Jul 21, 2023

Amarin Corporation plc, Annual General Meeting, Jun 21, 2023

Amarin Corporation plc Highlights New Data Providing Potential Mechanistic Insight into Vascepa(R)/Vazkepa(R) (Icosapent Ethyl)

Consensus EPS estimates fall by 11%

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased by 24% to US$2.70

Consensus EPS estimates fall by 21%

Full year 2022 earnings released: US$0.26 loss per share (vs US$0.02 profit in FY 2021)

Sarissa Capital Releases Investor Presentation to Shareholders of Amarin Corporation

Sarissa Capital Management Issues a Statement Regarding Amarin Corporation

Sarissa Capital Management Issues a Statement Regarding Amarin Corporation

Sarissa Capital Discloses its Views on Amarin Corporation

Sarissa Capital Warns of Amarin’s Expensive Attempts to Switch Votes by Inundating Shareholders with White Proxy Cards

Sarissa Capital Issues a Press Release to Shareholders of Amarin Corporation

Sarissa Capital Issues a Letter to Shareholders of Amarin Corporation

Sarissa Capital Issues a Social Media Post by Alexander J. Denner Relating to Amarin Corporation

Sarissa Capital Issues a presentation to Shareholders of Amarin Corporation

Sarissa Capital Issues an Investor Presentation to Shareholders of Amarin Corporation

Amarin Corporation plc, Annual General Meeting, Feb 28, 2023

Amarin Corporation Provides Information to Shareholders

Amarin Corporation plc Announces VAZKEPA (Icosapent Ethyl) Approved By Medsafe In New Zealand

Sarissa Capital Calls Out Amarin’s Sham Board Refreshment

Sarissa Capital Sends a Requisition Notice to Amarin Corporation

Sarissa Capital Sends a Requisition Notice to Amarin Corporation

Amarin Corporation plc Provides Revenue Guidance for the the Fourth Quarter and Full Year 2022

High number of new directors